Nuvo Pharmaceuticals (MRV) Stock Price, News & Analysis

Company Overview

Nuvo Pharmaceuticals Inc., doing business as Miravo Healthcare, provides prescription and non-prescription products for pain, allergy, neurology, and dermatology worldwide. The company operates in three segments: Commercial Business, Production and Service Business, and Licensing and Royalty Business. It offers Blexten, an antihistamine drug for the symptomatic relief of allergic rhinitis and chronic spontaneous urticaria; Cambia, a nonsteroidal anti-inflammatory drug for migraine; Suvexx/Treximet, a migraine medicine; NeoVisc, an injectable viscosupplement for osteoarthritis; and Resultz, FullMarks, and LAUSBUB for head lice infestations. The company also provides Bezalip SR for patients with high cholesterol or high levels of triglycerides; Proferrin, an iron supplement for the prevention and treatment of iron deficiency; Fiorinal 1 and Fiorinal C1 for the relief of tension-type headaches; Collatamp G for surgical implantation during surgery; PegaLAX, a laxative for the treatment of occasional constipation and irregularity; Mutaflor, a probiotic for the management and relief of chronic constipation and associated abdominal pain and cramps; MoviPrep for the cleansing of the colon in preparation for colonoscopy; and Soriatane to treat psoriasis and other keratinization disorders. In addition, it offers Pennsaid and Pennsaid 2% topical treatments for osteoarthritic pain; Vimovo for relief of arthritis symptoms; SYNERA and RAPYDAN topical patches used to help prevent pain associated with needle sticks and other superficial skin procedures; Yosprala for the prevention of heart attacks and strokes; and Heated Lidocaine/Tetracaine Patch, a topical patch applied prior to painful medical procedures. The company was formerly known as Nuvo Research Inc. and changed its name to Nuvo Pharmaceuticals Inc. in March 2016. Nuvo Pharmaceuticals Inc. was incorporated in 1983 and is headquartered in Mississauga, Canada.

Key Stats

• Today's Range: N/A
• 50-Day Range: C$1.35 to C$1.35
• 52-Week Range: N/A
• Volume: 6,732 shs
• Average Volume: 27,569 shs
• Market Capitalization: C$15.38 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

MRV Stock Analysis - Frequently Asked Questions

How do I buy shares of Nuvo Pharmaceuticals?

Shares of MRV stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

What other stocks do shareholders of Nuvo Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Nuvo Pharmaceuticals investors own include Biora Therapeutics (BIOR), ACM Research (ACMR), Achieve Life Sciences (ACHV), Achilles Therapeutics (ACHL), Adicet Bio (ACET), Acer Therapeutics (ACER) and Air Canada (AC).

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: TSE:MRV
• CIK: N/A
• Web: www.miravohealthcare.com
• Phone: N/A
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): C($0.07)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: C$15.17 million
• Net Margins: 20.95%
• Pretax Margin: N/A
• Return on Equity: 1,180.47%
• Return on Assets: 5.85%

Debt

• Debt-to-Equity Ratio: 1,165.85
• Current Ratio: 2.11
• Quick Ratio: 1.68

Sales & Book Value

• Annual Sales: C$72.42 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 0.23
• Book Value: C$0.75 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 11,390,000
• Free Float: N/A
• Market Cap: C$15.38 million
• Optionable: Not Optionable
• Beta: 0.78